Ryan Bruce Corcoran, M.D.
This page shows the publications co-authored by Ryan Corcoran and Keith Flaherty.
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med. 2013 Jul 31; 5(196):196ra98.
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012 Mar; 2(3):227-35.
A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. Oncoimmunology. 2018; 7(5):e1423172.
Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017 10 26; 8(1):1136.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.